Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement.
On May 25, 2018, Titan Pharmaceuticals, Inc. (the “Company” or “Titan”) entered into a Termination and Transition Services Agreement (the “Agreement”) with Braeburn Pharmaceuticals, Inc. (“Braeburn”) to which Titan will regain all rights to the commercialization and clinical development of Probuphine in the United States and Canada. Braeburn has paid Titan $1,000,000 and will provide assistance to Titan through December 28, 2018 to enable a smooth transition and ensure that patients and their doctors will continue to have support and access to this treatment. In addition, the Agreement provides for the immediate transfer to Titan all regulatory documentation and development data related to Probuphine.
Copies of the Agreement and the press release issued in connection therewith are attached hereto as Exhibits 10.1 and 99.1, respectively, and incorporated herein by reference.
Item 1.02. Termination of a Material Definitive Agreement.
The information set forth under Item 1.01 is hereby incorporated by reference into this Item 1.02 of this report.
Item 9.01. Financial Statements and Exhibits.
± Confidential treatment has been requested with respect to portions of this exhibit.
TITAN PHARMACEUTICALS INC ExhibitEX-10.1 2 tv495422_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. TERMINATION AND TRANSITION SUPPORT AGREEMENT THIS TERMINATION AND TRANSITION SUPPORT AGREEMENT (the “Agreement”) is made as of May 25,…To view the full exhibit click here
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
